CLINICAL TRIALS PROFILE FOR JETREA

All Clinical Trials for JETREA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02035748 ↗	Assessment of Patients Treated With JETREA® for Vitreomacular Traction	Completed	Alcon Research	Phase 4	2014-04-01	The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.
NCT02322229 ↗	Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion	Completed	Alcon Research	Phase 4	2015-05-26	The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
NCT02747030 ↗	Phase I RVC With Ocriplasmin for CRVO	Completed	Katholieke Universiteit Leuven	Phase 1	2016-12-01	In central retinal vein occlusion (CRVO) a blood clot blocks the venous outflow of the entire retinal circulation. This leads to retinal and vitreous hemorrhages, retinal edema and neovascularization. The development of a microneedle and surgical stabilizer made it possible to perform a prolonged (10 minutes) retinal vein cannulation with infusion of Ocriplasmin. Ocriplasmin has the advantage over tissue Plasminogen Activator (tPA) that it already is an active enzyme and a strong fibrinolyticum. This study aims to investigate the feasibility and safety of local intravenous Ocriplasmin for CRVO.
NCT02747030 ↗	Phase I RVC With Ocriplasmin for CRVO	Completed	KU Leuven	Phase 1	2016-12-01	In central retinal vein occlusion (CRVO) a blood clot blocks the venous outflow of the entire retinal circulation. This leads to retinal and vitreous hemorrhages, retinal edema and neovascularization. The development of a microneedle and surgical stabilizer made it possible to perform a prolonged (10 minutes) retinal vein cannulation with infusion of Ocriplasmin. Ocriplasmin has the advantage over tissue Plasminogen Activator (tPA) that it already is an active enzyme and a strong fibrinolyticum. This study aims to investigate the feasibility and safety of local intravenous Ocriplasmin for CRVO.
NCT02747030 ↗	Phase I RVC With Ocriplasmin for CRVO	Completed	Universitaire Ziekenhuizen Leuven	Phase 1	2016-12-01	In central retinal vein occlusion (CRVO) a blood clot blocks the venous outflow of the entire retinal circulation. This leads to retinal and vitreous hemorrhages, retinal edema and neovascularization. The development of a microneedle and surgical stabilizer made it possible to perform a prolonged (10 minutes) retinal vein cannulation with infusion of Ocriplasmin. Ocriplasmin has the advantage over tissue Plasminogen Activator (tPA) that it already is an active enzyme and a strong fibrinolyticum. This study aims to investigate the feasibility and safety of local intravenous Ocriplasmin for CRVO.

Clinical Trial Conditions for JETREA

Condition Name

Condition Name for JETREA
Intervention	Trials
Vitreomacular Adhesion	2
Vitreomacular Traction	2
Central Retinal Vein Occlusion	1

Condition MeSH

Condition MeSH for JETREA
Intervention	Trials
Tissue Adhesions	2
Retinal Vein Occlusion	1

Clinical Trial Locations for JETREA

Trials by Country

Trials by Country for JETREA
Location	Trials
Belgium	1
United States	1
Australia	1

Trials by US State

Trials by US State for JETREA
Location	Trials
Texas	1

Clinical Trial Progress for JETREA

Clinical Trial Phase

Clinical Trial Phase for JETREA
Clinical Trial Phase	Trials
Phase 4	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for JETREA
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for JETREA

Sponsor Name

Sponsor Name for JETREA
Sponsor	Trials
Alcon Research	2
Universitaire Ziekenhuizen Leuven	1
Katholieke Universiteit Leuven	1

Sponsor Type

Sponsor Type for JETREA
Sponsor	Trials
Other	3
Industry	2